Study on Managing Gastrointestinal Bleeding in Adults Taking Direct Oral Anticoagulants Using Prothrombin Complex at Strasbourg University Hospitals

What this Trial Is About

Gastrointestinal bleeding GIB is a frequent emergency in liver and digestive health, with death rates between 5% and 10% depending on the study. GIB is divided into upper GIB and lower GIB, with upper cases making up 80%. Many factors increase the risk of GIB, including the use of blood thinners called direct oral anticoagulants DOACs. When severe bleeding occurs under these medications, current guidelines recommend stopping the treatment and correcting blood clotting based on bleeding severity and clotting risk. However, the role, safety, and effectiveness of prothrombin complex concentrate PCC in this situation is uncertain due to limited research. This observational study analyzes how reversal treatments like PCC are used in patients with gastrointestinal bleeding who are taking DOACs. It focuses on patients admitted to the emergency department of Strasbourg University Hospital. The study tracks patients over 48 hours following admission to document treatment practices and outcomes without introducing new treatments or randomization. Participants will be monitored closely during their emergency department stay, with data collected on their bleeding management and anticoagulant reversal methods. Researchers will measure the proportion of patients on DOACs admitted for gastrointestinal bleeding and observe how coagulation is corrected. This will help understand current practices and outcomes related to PCC use and other treatments in this critical setting. The study runs until June 2026 and does not involve experimental interventions or placebo.

Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants